Literature DB >> 30184092

Therapeutic Monoclonal Antibodies and the Value of the Free Light Chain Assay in Myeloma.

Ishwarlal Jialal1,2, Roma Pahwa3, Rose C Beck4, Christine L Schmotzer5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30184092      PMCID： PMC6454534          DOI： 10.1093/ajcp/aqy110

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN： 0002-9173            Impact factor:   2.493


× No keyword cloud information.
  4 in total

Review 1.  Analytical issues of serum free light chain assays and the relative performance of polyclonal and monoclonal based reagents.

Authors:  Hugh D Carr-Smith; Ellen L Jenner; Josie A R Evans; Stephen J Harding
Journal:  Clin Chem Lab Med       Date:  2016-06-01       Impact factor: 3.694

2.  Quantification of daratumumab in the serum protein electrophoresis.

Authors:  Ishwarlal Jialal; Roma Pahwa
Journal:  Clin Chem Lab Med       Date:  2017-02-01       Impact factor: 3.694

3.  Investigation into the interference of the monoclonal antibody daratumumab on the free light chain assay.

Authors:  Aaron Seth Rosenberg; Scott Bainbridge; Roma Pahwa; Ishwarlal Jialal
Journal:  Clin Biochem       Date:  2016-07-28       Impact factor: 3.281

4.  Interference of Therapeutic Monoclonal Antibodies With Routine Serum Protein Electrophoresis and Immunofixation in Patients With Myeloma: Frequency and Duration of Detection of Daratumumab and Elotuzumab.

Authors:  Felicia Tang; Ehsan Malek; Susan Math; Christine L Schmotzer; Rose C Beck
Journal:  Am J Clin Pathol       Date:  2018-07-03       Impact factor: 2.493
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.